COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Reduced Anti-Platelet Therapy With Pimecrolimus Drug Eluting Stent (RAPID)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00322543
Recruitment Status : Terminated
First Posted : May 8, 2006
Last Update Posted : October 17, 2008
Information provided by:
Conor Medsystems

Brief Summary:
Non-randomized, single arm, multi-center, clinical trial evaluating the Corio™ pimecrolimus-eluting stent with reduced anti-platelet therapy in patients with de novo lesions of the native coronary arteries.

Condition or disease Intervention/treatment Phase
Coronary Disease Device: Corio™ Pimecrolimus-eluting stent Phase 3

Detailed Description:
The registry is designed to evaluate 6-month in-stent late lumen loss in patients receiving the Corio™ drug-eluting stent.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 3 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Reduced Anti-Platelet Therapy With Pimecrolimus Drug Eluting Stent (RAPID) A Multi-Center Study of the Pimecrolimus-Eluting Cobalt Chromium Coronary Stent System (Corio™) in Patients With De Novo Lesions of the Native Coronary Arteries
Study Start Date : May 2006
Actual Primary Completion Date : November 2006
Actual Study Completion Date : May 2008

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Drug eluting stent
Corio™ Pimecrolimus-eluting stent
Device: Corio™ Pimecrolimus-eluting stent

Primary Outcome Measures :
  1. Angiographic endpoint of in-stent late lumen loss at 6 months [ Time Frame: 6 months ]

Secondary Outcome Measures :
  1. Major Adverse Cardiac Events (MACE) defined as an adjudicated composite of clinically driven target vessel revascularization, new myocardial infarction (MI) or cardiac death at 30 days, 6 months, 12 months and 2 years; [ Time Frame: 30 days, 6 months, 12 months and 2 years ]
  2. Device, Lesion and Procedural Success; Coronary angiography at 6 months; IVUS measurements in IVUS cohort at 6 months. [ Time Frame: 6 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

General Inclusion Criteria

  1. Eligible for percutaneous coronary intervention (PCI).
  2. Documented stable or unstable angina pectoris
  3. Left ventricular ejection fraction (LVEF) ≥25%
  4. Acceptable candidate for coronary artery bypass graft surgery (CABG).
  5. Target Lesion < 25 mm in length with RVD of 2.5 to 3.5 mm with visually estimated stenosis of >= 50 and < 100 %.

Exclusion Criteria:

General Exclusion Criteria

  1. Known sensitivity to pimecrolimus, the polymer (PLGA) or cobalt chromium.
  2. Planned treatment with any other PCI device in the target vessel(s).
  3. MI within 72 hours prior to the index procedure
  4. The patient is in cardiogenic shock.
  5. Cerebrovascular Accident (CVA) within the past 6 months.
  6. Acute or chronic renal dysfunction
  7. Contraindication to ASA or to clopidogrel.
  8. Thrombocytopenia
  9. Active gastrointestinal (GI) bleeding within the past 3 months.
  10. Any prior true anaphylactiod reaction to contrast agents
  11. Patient is currently taking chronic systemic steroid therapy or systemic immunosuppressant therapy or topical pimecrolimus.
  12. Female of childbearing potential.
  13. Life expectancy of less than 24 months due to other medical conditions.
  14. Co-morbid condition(s)
  15. Currently participating in another investigational drug or device study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00322543

Layout table for location information
Institute Dante Pazzanese of Cardiology
Sao Paulo, SP, Brazil, 04012-180
Sponsors and Collaborators
Conor Medsystems
Layout table for investigator information
Principal Investigator: Alexandre Abizaid, M.D. Institute Dante Pazzanese of Cardiology
Layout table for additonal information
Responsible Party: Alexandre Abizaid, MD, Institute Dante Pazzanese of Cardiology Identifier: NCT00322543    
Other Study ID Numbers: RAPID (Genesis) Registry CP-02
First Posted: May 8, 2006    Key Record Dates
Last Update Posted: October 17, 2008
Last Verified: September 2008
Keywords provided by Conor Medsystems:
Percutaneous coronary intervention (PCI)
Drug eluting stent (DES)
Additional relevant MeSH terms:
Layout table for MeSH terms
Coronary Disease
Myocardial Ischemia
Heart Diseases
Cardiovascular Diseases
Vascular Diseases
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Dermatologic Agents
Immunosuppressive Agents
Immunologic Factors
Calcineurin Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action